Article 15321

Title of the article

Significance of TNFRSF11 gene polymorphism in bone resorption reguluation as a pathogenetic factor of yersinia arthritis development 

Authors

Ol'ga Nikolaevna Domashenko, Doctor of medical sciences, professor, head of the sub-department of infectious diseases, Donetsk National State University named after M. Gorky (16 Ilyicha avenue, Donetsk, Ukraine), E-mail: o_domashenko@mail.ru
Mariya S. Kishchenya, Candidate of medical sciences, senior staff scientist, head of the department of chromatographic studies, Central Research Laboratory, Donetsk National State University named after M. Gorky (16 Ilyicha avenue, Donetsk, Ukraine), E-mail: Maria.kishenya@gmail.com
Vitaliy A. Gridasov, Assistant of the sub-department of infectious diseases, Donetsk National State University named after M. Gorky (16 Ilyicha avenue, Donetsk, Ukraine), E-mail: gridasov_doc@mail.ru
Petr A. Chernobrivtsev, Candidate of medical sciences, senior staff scientist, head of the department of molecular genetic research, Central Research Laboratory, Donetsk National State University named after M. Gorky (16 Ilyicha avenue, Donetsk, Ukraine), E-mail: peter.chernobryvtsev@gmail.com 

Index UDK

616.72+616.98]-002-092:616.71-003.95+575 

DOI

10.21685/2072-3032-2021-3-15 

Abstract

Background. СDC (USА) places yersiniosis in ten intestinal infections which are subject to close observation. Exposure to multiple agents is responsible for possible damages of the joints at infection diseases acting as rare forms however, as a pathognomonic syndrome it is found at yersiniosis infections, brucellosis, and Lyme borreliosis. Studies of fine mechanisms of infection arthritis development do gain their relevance. The purpose of the research was to study the TNFRSF11B gene’s Asn3Lys polymorphic marker distribution at patients suffering from generalized and arthritic form of yersiniosis, and to determine the connection of the polymorphism in question with development of yersiniosis arthritis (YA). Materials and methods 123 patients aged 16 to 68 years, with proven yersiniosis infection, were observed. The 1st group included 61 patients with secondary focal arthritic form of yersiniosis whereas the 2nd control group consisted of 62 patients with generalized form of yersiniosis without damaging of joints. 50 patients (82 %) had chronic form of YA. For genetic tests, SNP–express test system – 31Т>С of IL1β gene and Asn3Lys of TNFRSF11B gene was applied. Results. In 2 groups of examined persons, three genotypes being Asn/Asn, Asn/Lys and Lys/Lys were detected. The incidence for genotype Asn/Asn in group with YA made 19.7 %, being 1,7 times lower as compared with control group (33.9 %). The genotype Lys/Lys in group with YA was detected with incidence 31.1 %, which is 2.14 times higher than the value for control group. The genotype Lys/Lys was found prevailing for patients with YA. Genotype Lys/Lys relates to increased risk of development of YA (χ2 = 6.08, р = 0.49; OR = 2.66, confidence interval 1.09–6.49). Coclusions. Polymorphism of Asn3Lys of TNFRSF11B gene coding the osteoprotegerin relates to development of YA. Genotype Lys/Lys of TNFRSF11B gene is a marker of increased risk of development and progressing of YA. Study of genetic predisposition to occurrence of YA, аs well as possible genetically determined resistance to treatment performed based on molecular and genetic testing is an important predictor for YA treatment and prevention. 

Key words

yersiniosis arthritis, bone resorption, osteoprotegerin, TNFRSF11B gene 

Download PDF
References

1. Agababova E.R., Bunchuk N.V., Shubin S.V., Urumova M.M., Soldatova S.I. Criteria for the diagnosis of reactive arthritis (project). Nauchno-prakticheskaya revmatologiya = Scientific and practical rheumatology. 2003;(3):82–83. (In Russ.)
2. Popova O.V., Shepeleva G.K., Shestakova I.V., Yushchuk N.D. Immunological aspects of the development of reactive arthritis in yersiniosis infection. Infektsionnye bolezni = Infectious diseases. 2006;4(2):53–58. (In Russ.)
3. Belov B.S., Shubin S.V., Balabanova R.M., Erdes Sh.F. Reactive arthritis. Nauchnoprakticheskaya revmatologiya = Scientific and practical rheumatology. 2015;(4):414–420. (In Russ.)
4. Shestakova I. V., Yushchuk N. D., Popova T. I. Yersiniosis: diagnostic mistakes. Vrach = The Doctor. 2007;(7):71–74. (In Russ.)
5. Domashenko O.N., Gridasov V.A. The role of yersinia in the pathology of the musculoskeletal system. Dni revmatologii v Sankt-Peterburge: Vseross. kongress s mezhdunar. uchastiem (Rossiya, g. Sankt-Peterburg 1–3 noyabrya 2018) = Days of rheumatology in Sain Petersburg: the All-Russian congress with international participation (Russia, Sain Petersburg, November 1-3, 2018). Saint Petersburg, 2018:71–72. (In Russ.)
6. Pesce Viglietti A.I., Arriola Benitez P.C., Gentilini M.V. [et al.]. Brucella abortus Invasion of Osteocytes Modulates Connexin 43 and Integrin Expression and Induces Osteoclastogenesis via Receptor Activator of NF – κB Ligand and Tumor Necrosis Factor Alpha Secretion. Infect. Immun. 2015;84(1):11–20. Available at: https://www.ncbi.nlm. nih.gov/pubmed/26459511
7. Chen W., Foo S.S., Rulli N.E. [et al.]. Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. Proc. Natl. Acad. Sci U S A. 2014;111(16):6040–6045. Available at: https://www.ncbi.nlm.nih.gov/pubmed/ 24733914
8. Fiore S.E., Riccobene S., Mangiafico R. [et al.]. Hepatitis C–associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. Osteoporos Int. 2005;16(12):2180–2184.
9. Titanji K., Vunnava A., Foster A. [et al.]. T–cell receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance is associated with HIV–induced bone loss in patients with higher CD4+ T–cell counts. AIDS. 2018;32(7):885–894. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29424771
10. Shestakova I. V., Yushchuk N. D. Chronic yersiniosis as a therapeutic problem. Terapevticheskiy arkhiv = Therapeutic archive. 2010;82(3):71–77. (In Russ.)
11. Yersinia enterocolitica (Yersiniosis). Available at: https://www.cdc.gov/yersinia/ faq.html
12. Selmi C., Gershwin M.E. Diagnosis and classification of reactive arthritis. Autoimmunity Reviews. 2014;(13):546–549.
13. Tennant S.M., Robins-Browne R.M., Grant T.N. Pathogenicy of Yesinia enterocolitica biotype 1A. Immunology and Medical Microbiology. 2003;38:127–137.
14. Hengartner N., Fiedler J., Ignatius A. [et al.]. IL–1β inhibits human osteoblast migration. Mol. Med. 2013;19:36–42.
15. Hsu Y.H., Niu T., Terwedow N.A. [et al.]. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral densi-ty at different skeletal sites in men. Hum. Genet. 2006;118:568–577.
16. Richards J.B., Rivadeneira F., Inouye M. [et al.]. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet. 2008;371:1505–1512.
17. Rebrova O.Yu. Statisticheskiy analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA = Statistical analysis of medical data. Using an application program STATISTICA. Moscow: MediaSfera, 2003:312. (In Russ.)

 

Дата создания: 23.11.2021 14:21
Дата обновления: 25.11.2021 13:37